FMI News Alert Foundation Medicine Inc (FMI) 23.99 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Foundation Medicine Inc (FMI) 23.99 $FMI

Twitter's Favorite Biotech and Pharma Stocks
Brian Orelli, The Motley Fool - Motley Fool - Tue Dec 16, 8:21AM CST
Mark Schoenebaum, the biotech and pharmaceutical analyst at Evercore ISI, asked the Twittersphere for their favorite drug stocks going into next year. What's your favorite stock for 2015 in biotech or Pharma? — Mark Schoenebaum...
BLUE: 88.76 (+3.23), BMRN: 88.18 (+0.89), TGTX: 16.03 (+0.33), BMY: 59.15 (-0.01), MACK: 10.91 (+0.36), FMI: 23.99 (-0.10), RNA: 18.76 (+0.10), GWPH: 68.08 (+1.82), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), ICPT: 151.49 (+5.85), THLD: 2.93 (+0.01), CEMP: 20.66 (+0.78), NVS: 93.91 (+0.66)

Foundation Medicine to Be Added to NASDAQ Biotechnology Index
Business Wire - Tue Dec 16, 5:30AM CST
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the Company will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior to the market open on Monday, December 22, 2014.
FMI: 23.99 (-0.10), IBB: 299.80 (+5.12)

Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST

TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

FoundationOne(R) Identifies Clinically Relevant Genomic Alterations in Patients with Advanced Breast Cancers
Business Wire - Tue Dec 09, 8:01AM CST
Foundation Medicine, Inc. (NASDAQ:FMI) today announced new data further demonstrating the clinical utility of FoundationOne(R) across several types of breast cancer, including metastatic and inflammatory breast cancer. Collectively, these studies support the use of comprehensive genomic profiling to identify distinct genomic alterations that may further tailor treatment options and result in improved outcomes for patients with breast cancer. These data are being presented by Foundation Medicine and its collaborators during the 2014 San Antonio Breast Cancer Symposium.
FMI: 23.99 (-0.10)

New Clinical Data Supports the Use of FoundationOne(R) Heme to Enable Informed Treatment Decisions in a Wide Range of Hematologic Malignancies
Business Wire - Tue Dec 09, 5:30AM CST
Foundation Medicine, Inc. (NASDAQ:FMI) today announced new data demonstrating that FoundationOne(R) Heme, developed in collaboration with Memorial Sloan Kettering Cancer Center, provides critical genomic information that can impact prognosis, influence therapeutic strategy and even refine conventional pathologic diagnosis in patients with a wide range of hematologic malignancies. Collectively, these data highlight the potentially transformative impact of FoundationOne Heme across all aspects of cancer care. These findings were presented in two posters and an oral presentation at the American Society of Hematology Annual Meeting in San Francisco.
FMI: 23.99 (-0.10)

Treatment for Relapsed Multiple Myeloma Patients Guided by FoundationOne(R) Heme Results in Promising Clinical Activity
Business Wire - Mon Dec 08, 12:00PM CST
Foundation Medicine, Inc. (NASDAQ:FMI) today announced new data demonstrating that its comprehensive genomic profile, FoundationOne(R) Heme, identified genomic alterations in patients with heavily pre-treated multiple myeloma that informed treatment with trametinib, an FDA-approved targeted therapeutic agent(1). Notably, 68% of total patients who underwent treatment based on results provided by FoundationOne Heme experienced clinical benefit, supporting the clinical utility of this test in patients with refractory or relapsed multiple myeloma for whom other treatment options have largely been exhausted.
FMI: 23.99 (-0.10)

Foundation Medicine and Collaborators to Present New Clinical Data on the Application of FoundationOne(R) in Breast Cancer at the 2014 San Antonio Breast Cancer Symposium
Business Wire - Wed Dec 03, 5:30AM CST
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that eight abstracts highlighting new clinical data on the application of FoundationOne(R) in patients with breast cancer will be presented at the 37th Annual San Antonio Breast Cancer Symposium (SABCS) taking place December 9-13, 2014, at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
FMI: 23.99 (-0.10)

Foundation Medicine Appoints David J. Daly as Chief Commercial Officer
Business Wire - Tue Dec 02, 4:30PM CST
Foundation Medicine, Inc. (NASDAQ:FMI) today announced the appointment of David J. Daly to the role of chief commercial officer. Mr. Daly brings more than 25 years of proven commercial experience in both emerging and Fortune 500 clinical diagnostics and oncology companies to his new role leading Foundation Medicine's commercial organization. Mr. Daly will report to president and chief executive officer, Michael J. Pellini, M.D.
FMI: 23.99 (-0.10)

Foundation Medicine and Flatiron Health Collaborate to Develop First-in-Class Data Platform to Accelerate Precision Medicine for Cancer
Business Wire - Tue Dec 02, 5:30AM CST
Foundation Medicine, Inc. (NASDAQ:FMI) and Flatiron Health today announced a strategic collaboration to develop a unique, proprietary cloud-based information platform combining genomic and clinical treatment and outcomes data to significantly advance the field of precision medicine for cancer.
FMI: 23.99 (-0.10)

Foundation Medicine to Present at the Piper Jaffray Healthcare Conference
Business Wire - Tue Nov 25, 5:30AM CST
Foundation Medicine, Inc. (NASDAQ:FMI) today announced Steven J. Kafka, Ph.D., chief operating officer, is scheduled to present at the Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014, at 3:30 p.m. E.T. in New York City.
FMI: 23.99 (-0.10)

Foundation Medicine's Novel Companion Diagnostic Test, Developed in Collaboration with Clovis Oncology, Identifies Expanded Subgroup of Cancer Patients with the Potential to Respond to Clovis Oncology's PARP inhibitor, Rucaparib
Business Wire - Wed Nov 19, 5:05PM CST
Foundation Medicine, Inc. (NASDAQ: FMI) today announced the presentation of new data from its ongoing collaboration with Clovis Oncology (NASDAQ: CLVS) to develop a novel companion diagnostic test to identify patients who have the potential to benefit from rucaparib, Clovis Oncology's poly (ADP-ribose) polymerase inhibitor (PARPi). These new data suggest that Foundation Medicine's novel companion diagnostic can identify both BRCA-mutant patients and non BRCA-mutant patients who are more likely to benefit from rucaparib than patients who are biomarker negative.
FMI: 23.99 (-0.10), CLVS: 54.58 (+0.43)

Foundation Medicine Winning Increased Insurance Coverage for Genetic Cancer Tests
at The Street - Wed Nov 19, 10:17AM CST
Coverage decisions are still likely to slowly build over time but it is a clear positive that we are seeing the early adopters start to reimburse for Foundation's cancer tests.
FMI: 23.99 (-0.10)

Foundation Medicine to Present at Upcoming Investor Conferences
Business Wire - Thu Nov 13, 5:30AM CST
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at the following upcoming investor conferences:
FMI: 23.99 (-0.10)

The Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute Partner with Foundation Medicine to Launch Innovative Clinical Translation Program
Business Wire - Wed Nov 12, 7:01AM CST
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University (Lurie Cancer Center) and the Northwestern Medicine Developmental Therapeutics Institute (NMDTI) today announced the initiation of a new clinical translation program with Foundation Medicine, Inc. (NASDAQ: FMI) designed to assist in the development of oncology therapeutics and further expand the clinical utility of Foundation Medicine's comprehensive genomic profiling technologies.
FMI: 23.99 (-0.10)

Foundation Medicine's (FMI) CEO Michael Pellini on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 09, 5:36AM CST

FMI: 23.99 (-0.10)

Foundation Medicine Slumps: FMI Tumbles 9.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:59AM CST
Foundation Medicine has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
ABMD: 38.46 (+0.13), DXCM: 54.94 (+0.99), FMI: 23.99 (-0.10), ANGO: 19.19 (+0.33)

Foundation Medicine and Collaborators to Present New Clinical Data on FoundationOne(R) Heme at the American Society of Hematology Annual Meeting
Business Wire - Thu Nov 06, 9:58AM CST
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that 12 abstracts highlighting new clinical data on FoundationOne(R) Heme will be presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 6-9, 2014, at the Moscone Center in San Francisco.
FMI: 23.99 (-0.10)

"Don't Guess. Test." Campaign Aims to Educate Patients About Comprehensive Genomic Testing in Lung Cancer
Business Wire - Thu Nov 06, 7:02AM CST
The Bonnie J. Addario Lung Cancer Foundation (ALCF), in collaboration with Foundation Medicine and Friends of Cancer Research, and in partnership with many advocacy organizations, today launched the "Don't Guess. Test." campaign to expand awareness and educate patients about precision medicine and the importance of comprehensive genomic testing in lung cancer. Through extensive grassroots and social media efforts, the campaign's 16 lung cancer advocacy organizations are working throughout the country on this important collaborative initiative. Campaign partners include: American Lung Association, Cancer Care, Caring Ambassadors Program, Dusty Joy Foundation, Free Me, Free to Breathe, Lung Cancer Initiative of North Carolina, Lung Cancer Alliance, Lung Cancer Circle of Hope, Lung Cancer Foundation of America, Rexanna's Foundation, United Against Lung Cancer, Upstage Lung Cancer and We Wish Foundation.
FMI: 23.99 (-0.10)

Foundation Medicine beats Street 3Q forecasts
Automated Insights - Wed Nov 05, 4:39PM CST
CAMBRIDGE, Mass. (AP) _ Foundation Medicine Inc. (FMI) on Wednesday reported a third-quarter loss of $13 million.
FMI: 23.99 (-0.10)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Pepsi Faces Georgia Labor Pressure Ahead of Strike

Updated Category News Views 121

A Pre-Dawn Labor Test Is Brewing in Georgia At 2:30 in the morning, nobody gathers outside a distribution center for the scenery. More than 100 Pepsi-Cola drivers from Atlanta and Lithonia are slated to meet Tuesday, November 24, at the Pepsi Distribution Center in Lithonia, Georgia, with Teamsters General President Sean M. O'Brien joining them. That hour matters. It puts...

Continue Reading
Milwaukee County Contract Tests Wisconsin Labor Shift

Updated Category News Views 60

A unanimous first contract in a Milwaukee County department is not the sort of headline that rattles a trading screen, but it can tell you plenty about where the ground is moving. Public safety workers in the county Facilities Department have ratified their first agreement with Teamsters Local 344, according to the union. The vote matters less for any disclosed economic...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 149

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 83

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Straub's Court Win Raises Cost of Seven-Year Fight

Updated Category News Views 87

Seven years of courtroom smoke over an under-$80,000 lien is the sort of mess that makes any business owner grind his teeth. Palm Beach Polo says its president, Glenn Straub, has again prevailed against Jessica Nicodemo in Palm Beach County, following an earlier Broward County dismissal of related claims. The company also says Vice President Sal Spano received a directed...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 49

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Hoymiles Brings Plug-In Solar Flexibility to RE+ 2026

Updated Category News Views 105

A 1.8-kilogram box may not sound like much, but it captures where household solar is trying to go: smaller, less intimidating, and far easier to put to work. At RE+ 2026 in Las Vegas, Hoymiles laid out a residential lineup spanning plug-in solar, battery storage and conventional rooftop microinverters. This was not one flashy gadget looking for applause. It was a fairly...

Continue Reading

Top 5 Most Recently Viewed Articles

Hydreight Technologies Inc. Holds Successful Annual Meeting

Updated Category News Views 147

Successful Results from Hydreight Technologies Inc.'s Annual Meeting Hydreight Technologies Inc. (TSXV: NURS, OTC: HYDTF, FSE: SO6) proudly shares the positive outcomes from their recent Annual General Meeting. Conducted virtually, the meeting brought together shareholders who actively participated in decision-making. Shareholder Voting Outcomes During this significant...

Continue Reading
Discovering Leadership Themes in Anusia Gillespie's Novel

Updated Category News Views 146

Anusia Gillespie's Soul Toll: A Unique Literary Journey Soul Toll is gaining significant recognition for its imaginative storytelling which straddles the realms of ambition and awakening. This debut novel by Anusia Gillespie is becoming a staple not just in libraries, but also in yoga studios and leadership circles. Recognition from Kirkus Reviews The November issue of...

Continue Reading
First-Time Buyers' Guide to Stillwater's Housing Market

Updated Category News Views 64

The Challenge of Buying a Home in Stillwater Walking into Stillwater's housing market as a first-time buyer is like stepping onto a high-wire act. You're balancing dreams with dollars, all while the ground beneath you keeps shifting. What stands out from HelloNation's deep dive into this market, featuring Page Provence of Fisher Provence Realtors Inc., is that knowledge...

Continue Reading
Celebrating Excellence: National Catholic Reporter's 70 Awards

Updated Category News Views 127

Outstanding Achievement in Catholic Journalism The National Catholic Reporter (NCR) and its affiliated platforms, such as Global Sisters Report (GSR) and EarthBeat, have recently achieved remarkable recognition in the realm of Catholic media. With over 70 awards at the prestigious Catholic Media Awards, NCR has reaffirmed its dedication to delivering independent...

Continue Reading
Centessa Pharmaceuticals Prepares for Major Investor Events

Updated Category News Views 50

Centessa Pharmaceuticals' Upcoming Investor Conferences Centessa Pharmaceuticals plc (Nasdaq: CNTA), a pioneering clinical-stage pharmaceutical company, is set to mark its presence in several prominent investor conferences. The company's mission is to discover and develop transformative medicines aimed at enhancing patient outcomes. Guggenheim Healthcare Innovation...

Continue Reading